NCT05244980 is a Phase 1 clinical trial of TDM-105795 in Alopecia, Androgenetic, sponsored by Technoderma Medicines Inc..

Who is sponsoring NCT05244980?

NCT05244980 is sponsored by Technoderma Medicines Inc..

What drugs are being tested in NCT05244980?

Interventions in NCT05244980: TDM-105795, Placebo.

What condition does NCT05244980 study?

NCT05244980 studies Alopecia, Androgenetic.

Is NCT05244980 still recruiting?

NCT05244980 is currently completed. Last updated 14 March 2023.

Last reviewed 2023-03-14 · How we verify

NCT05244980

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

Completed Phase 1 Last updated 14 March 2023

What this trial tests

Phase 1 trial testing TDM-105795 in Alopecia, Androgenetic in 32 participants. Completed in 27 February 2023.

Timeline

1 February 2022

Primary endpoint
15 November 2022

27 February 2023

Quick facts

Lead sponsor	Technoderma Medicines Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	32
Start date	1 February 2022
Primary completion	15 November 2022
Estimated completion	27 February 2023
Sites	2 locations across United States

Drugs / interventions tested

TDM-105795 — full drug profile →
Placebo

Conditions studied

Alopecia, Androgenetic — all drugs for Alopecia, Androgenetic →

Sponsor

Technoderma Medicines Inc. — full company profile →

Who can join

Adults 18 to 55, male only, with Alopecia, Androgenetic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of TDM-105795

Trials testing the same drug.

NCT04913519 — A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA) · Phase 1 · completed

Other recruiting trials for Alopecia, Androgenetic

Currently open trials in the same condition.

NCT07011485 — A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia. · Phase 2 · active not recruiting

Other Technoderma Medicines Inc. trials

Trials by the same sponsor.

NCT06363461 — Study of TDM-180935 in Atopic Dermatitis Patients · Phase 2 · completed
NCT05802173 — Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia · Phase 2 · completed
NCT05525468 — A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects · Phase 1 · completed
NCT04913519 — A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA) · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05244980 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Technoderma Medicines Inc.
Last refreshed: 14 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05244980.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing